Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.
The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...
The initial report of a patient with visceral scleroderma without skin involvement was published in 1954, [1] and in 1962, the term "progressive systemic sclerosis sine scleroderma" was coined. [2] ...
Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt ...
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all ...
VIENNA — The use of immunosuppressive and antifibrotic drugs to treat skin and lung fibrosis leads updated recommendations from the European Alliance of Associations for Rheumatology (EULAR) for the ...
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- In 2021, the systemic scleroderma treatment market was valued at nearly US$ 749.4 Mn, and is estimated to expand at a CAGR of 8% over the forecast period ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback